Shantou Central Hospital
汕头市中心医院
Listed for 5 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
No official website checked for this hospital yet.
Research at Shantou Central Hospital
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Oesophageal squamous cell carcinoma食管鳞状细胞癌4 papers led
- Breast cancer乳腺癌6 papers led1 open trial led
- Beta thalassaemiaβ 地中海贫血0 papers led
- Fabry disease法布雷病0 papers led
- IgA nephropathyIgA 肾病0 papers led
Not listed for: Nasopharyngeal carcinoma, Hepatocellular carcinoma, Stomach cancer, Lung cancer, Pancreatic cancer, Glioma, Hepatoblastoma, Retinoblastoma, Chordoma, Osteosarcoma, Gastrointestinal stromal tumour, Neuroblastoma, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Lymphoma, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Coronary heart disease, Congenital heart disease, Scoliosis, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Oesophageal squamous cell carcinoma
食管鳞状细胞癌Led 4 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Shantou for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma
No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Papers it led4
- Validation of the Node Reporting and Data System (Node-RADS) for standardized CT evaluation of regional lymph nodes in esophageal squamous cell carcinoma patients.
- THBS1 promotes angiogenesis and accelerates ESCC malignant progression by the HIF-1/VEGF signaling pathway.
- First-line or second-line PD-1 inhibition in advanced oesophageal squamous cell carcinoma: A prospective, multicentre, registry study.
- Development and validation of a radiomics-based model to predict local progression-free survival after chemo-radiotherapy in patients with esophageal squamous cell cancer.
More papers found outside PubMed (not counted)5
- The prognostic value of microRNA‐200 family expression in digestive system tumors: A meta‐analysis and validation
- Induction immunochemotherapy conversion rate and survival outcomes versus chemotherapy in initially unresectable esophageal squamous cell carcinoma.
- Conversion surgery following immuno-chemotherapy in initially-unresectable esophageal squamous cell carcinoma: A real-world multicenter study.
- Characterization of epigenetic alterations in esophageal cancer by whole-genome bisulfite sequencing
- Development and Validation of a Radiomics-based Model to Predict Local Progression-free Survival After Chemo-radiotherapy in Patients With Esophageal Squamous Cell Cancer
Cancer
Breast cancer
乳腺癌Led 6 of the 16,974 English-language PubMed papers on breast cancer with an author in mainland China, 2021–2025: 0.04%.
2 hospitals in Shantou for breast cancer219 hospitals in China for breast cancer
Open trials with this hospital 6
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingNeoadjuvant Dose-dense Chemotherapy for HR+/HER2- Breast Cancer Patients With High Proliferation Index
- Phase
- Phase 2
- Started
- 2021-08
- Posted
- Registry
- NCT05728268
Age 18 years to 70 years; women only (registered criteria)
Led by Shantou Central HospitalShantou
- RecruitingRibociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy
- Phase
- Phase 3
- Started
- 2026-02
- Posted
- Registry
- NCT07400523
Age 18 years to Not stated; women only (registered criteria)
Led by Sun Yat-sen Memorial Hospital; 2 listed hospitals as study sitesGuangzhou, Shantou, Zhanjiang
- RecruitingA Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
- Phase
- Phase 3
- Started
- 2025-06
- Posted
- Registry
- NCT07003074
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesChangchun, Changsha, Hefei, Jinan, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Tianjin, Urumqi, Wuhan
- RecruitingA Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
- Phase
- Phase 3
- Started
- 2025-09
- Posted
- Registry
- NCT07043725
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 52 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Harbin, Hefei, Hengyang, Jinan, Lanzhou, Linyi, Luoyang, Luzhou, Meizhou, Nanchang, Nanjing, Nanning, Ningbo, Quanzhou, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Xi'an, Xinxiang, Yantai, Zhengzhou
- RecruitingA Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
- Phase
- Phase 3
- Started
- 2025-01
- Posted
- Registry
- NCT07673029
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 51 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linyi, Luoyang, Meizhou, Nanchang, Nanning, Qingdao, Quanzhou, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Weifang, Wuhan, Xi'an, Xinxiang, Xuzhou, Yantai, Zhengzhou
- RecruitingFulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer
- Phase
- Phase 3
- Started
- 2018-05
- Posted
- Registry
- NCT04263298
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesChangsha, Guangzhou, Nanning, Shantou, Shenzhen, Zhanjiang
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Papers it led6
- L-ICG as an optical agent to improve intraoperative margin detection in breast-conserving surgery: a prospective study.
- GLUT1 as a generic biomarker enables near-infrared fluorescence molecular imaging guided precise intraoperative tumor detection in breast cancer.
- Discrimination between HER2-overexpressing, -low-expressing, and -zero-expressing statuses in breast cancer using multiparametric MRI-based radiomics.
- Quantitative parameters of dynamic contrast-enhanced magnetic resonance imaging to predict lymphovascular invasion and survival outcome in breast cancer.
- Epidemiological characteristics and forecasting incidence for patients with breast cancer in Shantou, Southern China: 2006-2017.
- Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Pairwise and Network Meta-Analysis of Pathological Complete Response.
All its trials on ClinicalTrials.gov, any status12
- Neoadjuvant Dose-dense Chemotherapy for HR+/HER2- Breast Cancer Patients With High Proliferation Index
- Airwave Compression Therapy to Prevent Breast Cancer-related Lymphedema
- Serum and Tissue Metabolite-based Prediction of Sentinel Lymph Node Metastasis in Breast Cancer
- Lidocaine Mucilage-ICG as an Optical Agent for Tumor Delineation During Breast-conserving Surgery
- Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy
- A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
- A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
- A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
- Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer
- DIEP-MDS for Risk Stratification of Flap Vascular Compromise and Failure in Breast Reconstruction
- A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression.
- A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer
Blood disorders
Beta thalassaemia
β 地中海贫血Led no English-language PubMed papers on beta thalassaemia in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Shantou for beta thalassaemia133 hospitals in China for beta thalassaemia
No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Earlier papers (2016–2020)1
Other diseases
Fabry disease
法布雷病Led no English-language PubMed papers on Fabry disease in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
1 hospital in Shantou for Fabry disease80 hospitals in China for Fabry disease
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
- Phase
- Not given
- Started
- 2025-11
- Posted
- Registry
- NCT07187440
Age 7 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Nanjing, Shantou, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Xi'an
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
All its trials on ClinicalTrials.gov, any status1
Other diseases
IgA nephropathy
IgA 肾病Led no English-language PubMed papers on IgA nephropathy in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Shantou for IgA nephropathy300 hospitals in China for IgA nephropathy
No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
All its trials on ClinicalTrials.gov, any status1
Getting in touch
Name card to show staff or a driver
汕头市中心医院
Shantou Central Hospital
汕头
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
ROR
Affiliated Hospital of Shantou